



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
Patent Examining Operations

Application of : Mark E. Samuels et al.
Serial No. : 10/552,158 Art Unit: Unassigned
Filed : 11 December 2006 Examiner: Unassigned
For : Juvenile Hemochromatosis Gene (HFE2A), Expression Products and Uses Thereof
Docket No. : 760050-154

21 May 2006

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL

Sir:

Applicants herewith file the following:

1. Information Disclosure Statement (3 sheets);
2. Form 1449 (1 sheet) plus copies of 8 non-patent references;
3. Copy of Information Disclosure Statement for WO 2004/092405; and
3. Self-addressed, Postage-paid Return Postcard.

Applicant believes that no fees are required in filing these papers. The Commission is authorized to charge any fees, or credit any overpayment, to Deposit Acct. No. 03-0678.

FIRST CLASS CERTIFICATE

I hereby certify that this correspondence is being deposited today with the U.S. Postal Service as First Class Mail in an envelope addressed to:

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Alan J. Grant 5/21/07

Alan J. Grant, Esq. Date

Respectfully submitted,

Alan J. Grant

Alan J. Grant, Esq.
Reg. No. 33,389

CARELLA, BYRNE BAIN, GILFILLAN,
CECCHI, STEWART & OLSTEIN
5 Becker Farm Road
Roseland, NJ 07068
Phone: 973-994-1700
Fax: 973-994-1744



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Mark E. Samuels et al.
Serial No. : 10/552,158 Art Unit: Unassigned
Filed : 11 December 2006 Examiner: Unassigned
For : Juvenile Hemochromatosis Gene (HFE2A), Expression Products and Uses Thereof
Docket No. : 760050-154

21 May 2007

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

SIR:

Pursuant to 37 C.F.R. §1.56(a), Applicant(s) hereby cite(s) the enclosed documents listed on the attached copy of Form PTO-1449, which may be material to the patentability of the above-identified application. Applicant(s) make no admission that the cited references are prior art or that these references are in fact material to the patentability of the above-entitled application.

This Information Disclosure Statement is filed in accordance with the paragraph of 37 CFR §1.97 indicated below:

X §1.97(b) This Information Disclosure Statement is filed:

(1) Within three months of the filing date of a national application; OR

- (2) Within three months of the date of entry of the national stage of an international application; OR
- (3) Before the mailing of a first Office Action on the merits. No fee or statement is required.

 §1.97(c) This Information Disclosure Statement is filed after the period specified in paragraph (b) above, but before the mailing date of either:

- (1) A Final Action or under 37 CFR §1.113; OR
- (2) A Notice of Allowance under 37 CFR §1.311; AND

is accompanied by either: (check one)

- The statement as specified in 37 CFR §1.97(e) set out below; OR
- The fee of \$180.00 under 37 CFR §1.17(p).

 §1.97(d) This Information Disclosure Statement is filed after the mailing date of either:

- (1) a Final Action or under 37 CFR §1.113; OR
- (2) A Notice of Allowance under 37 CFR §1.311;

BUT filed on or before payment of the Issue Fee; AND
is accompanied by:

- (1) The statement as specified in 37 CFR §1.97(e) as set forth below; AND
- (2) Petition is hereby made under 37 CFR §1.97(d) for consideration of this Information Disclosure Statement; AND,
- (3) The petition fee of \$130.00 set out in 37 CFR §1.17(i).

 §1.97(e) The undersigned Attorney hereby states that:

- each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of this Information Disclosure Statement; or
- no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, or to the knowledge of the undersigned Attorney after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three

Serial No.: 10/552,158
Docket No. 689290-154

months prior to the filing date of the Information Disclosure Statement.

The Examiner is respectfully requested to consider and make of record all of the cited documents.

The Commissioner is authorized to charge payment of any fees associated with this communication or credit any overpayment to Deposit Account No. 03-0678.

FIRST CLASS CERTIFICATE

I hereby certify that this correspondence is being deposited today with the U.S. Postal Service as First Class Mail in an envelope addressed to:

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Alan J. Grant

5/21/07

Date

Respectfully submitted,



Alan J. Grant, Esq.
Reg. No. 33,389

CARELLA, BYRNE BAIN, GILFILLAN,
CECCHI, STEWART & OLSTEIN
5 Becker Farm Road
Roseland, NJ 07068
Phone: 973-994-1700
Fax: 973-994-1744



Form PTO-1449 INFORMATION DISCLOSURE STATEMENT			Atty. Docket: 760050-154		Serial No.: 10/552,158		
			Applicant: Mark E. Samuels				
			Filing Date: 11 December 2006		Group: 1645		
U.S. PATENT DOCUMENTS							
Examiner Initial		Document Number	Date	Name	Class	Sub-Class	Filing Date
	A1						
FOREIGN PATENT DOCUMENTS							
Examiner Initial		Document Number	Date	Country	Class	Sub-Class	Translation
	B1	WO 02/051438	4 July 2002	PCT			
	C1	WO 04/092405	28 October 2004	PCT			
	D1						
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)							
	E1	Afanassiev et al., Mutation Research, Vol. 464, pp. 297-308 (2000)					
	F1	Goldberg et al., Amer. J. Human Gen., Vol. 73, p. 205 (2003) (Abstract)					
	G1	Gonzalez et al., Curr. Opin. Biotechnology, Vol. 9, pp. 624-631 (1998)					
	H1	Hertzberg et al., Curr. Op. Chem. Biol., Vol. 4, pp. 445-451 (2000)					
	I1	Koller et al., Trends in Pharmacol. Sci., Vol. 21, pp. 142-148 (2000)					
	J1	Mattheakis et al., Chem. & Biol., Curr. Biol., Vol. 6, pp. 835-844 (1999)					
	K1	Pender et al., J. Med. Chem., Vol. 44, pp. 36-45 (2001)					
	L1	Taupin et al., J. Immun. Methods, Vol. 256, pp. 77-87 (2001)					
	M1						
	N1						
	O1						
	P1						
	Q1						
	R1						
Examiner:					Date Considered:		
EXAMINER:		Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.					